Although little is known about the function of KIT in ovarian cancer cells, the inhibition of KIT expression under thyrostimulin treatment might contribute to a reduction in KIT-mediated growth control and thus further promote ovarian cancer progression. Here, KIT is linked to ovarian carcinoma.